| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 25 | 2026 | 704 | 3.930 |
Why?
|
| Influenza Vaccines | 13 | 2026 | 499 | 2.590 |
Why?
|
| Rotavirus Vaccines | 14 | 2024 | 60 | 2.470 |
Why?
|
| Rotavirus Infections | 17 | 2024 | 281 | 2.390 |
Why?
|
| Hospitalization | 43 | 2026 | 1944 | 2.370 |
Why?
|
| Respiratory Tract Infections | 13 | 2025 | 293 | 2.090 |
Why?
|
| Gastroenteritis | 14 | 2025 | 307 | 1.890 |
Why?
|
| Respiratory Syncytial Virus Infections | 11 | 2026 | 385 | 1.800 |
Why?
|
| Vaccination | 23 | 2026 | 1041 | 1.670 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2026 | 190 | 1.450 |
Why?
|
| Infant | 65 | 2026 | 13343 | 1.200 |
Why?
|
| Rotavirus | 10 | 2024 | 366 | 1.130 |
Why?
|
| Antiviral Agents | 8 | 2026 | 814 | 1.110 |
Why?
|
| Child, Preschool | 56 | 2026 | 15089 | 0.960 |
Why?
|
| Immunization Programs | 5 | 2020 | 66 | 0.940 |
Why?
|
| Enterovirus Infections | 5 | 2025 | 48 | 0.910 |
Why?
|
| Child | 64 | 2026 | 26361 | 0.900 |
Why?
|
| Respiratory Syncytial Virus, Human | 6 | 2025 | 233 | 0.890 |
Why?
|
| United States | 48 | 2026 | 11846 | 0.800 |
Why?
|
| Case-Control Studies | 20 | 2026 | 3457 | 0.730 |
Why?
|
| Emergency Service, Hospital | 10 | 2025 | 1214 | 0.690 |
Why?
|
| Population Surveillance | 6 | 2025 | 397 | 0.680 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 4 | 2026 | 80 | 0.680 |
Why?
|
| Prospective Studies | 22 | 2025 | 6539 | 0.660 |
Why?
|
| Reassortant Viruses | 3 | 2016 | 28 | 0.610 |
Why?
|
| Infant, Newborn | 29 | 2026 | 8613 | 0.610 |
Why?
|
| Adolescent | 39 | 2026 | 21018 | 0.610 |
Why?
|
| Epidemiological Monitoring | 3 | 2018 | 69 | 0.600 |
Why?
|
| Metapneumovirus | 3 | 2025 | 53 | 0.590 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 7 | 2026 | 128 | 0.580 |
Why?
|
| Humans | 94 | 2026 | 132041 | 0.570 |
Why?
|
| Enterovirus D, Human | 3 | 2025 | 11 | 0.550 |
Why?
|
| Arbovirus Infections | 1 | 2018 | 30 | 0.550 |
Why?
|
| Viruses | 3 | 2024 | 118 | 0.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2026 | 573 | 0.530 |
Why?
|
| Seasons | 9 | 2026 | 338 | 0.520 |
Why?
|
| Fever | 2 | 2024 | 312 | 0.510 |
Why?
|
| Female | 60 | 2026 | 71380 | 0.510 |
Why?
|
| Paramyxoviridae Infections | 3 | 2025 | 49 | 0.490 |
Why?
|
| Male | 58 | 2026 | 65425 | 0.490 |
Why?
|
| Reminder Systems | 2 | 2016 | 62 | 0.490 |
Why?
|
| Immunization | 2 | 2021 | 269 | 0.470 |
Why?
|
| Adenoviruses, Human | 2 | 2025 | 97 | 0.450 |
Why?
|
| Adenovirus Infections, Human | 2 | 2025 | 60 | 0.440 |
Why?
|
| Picornaviridae Infections | 2 | 2025 | 50 | 0.420 |
Why?
|
| Immunization Schedule | 6 | 2026 | 111 | 0.420 |
Why?
|
| Acute Disease | 8 | 2025 | 1153 | 0.420 |
Why?
|
| Texas | 13 | 2026 | 3646 | 0.410 |
Why?
|
| Enterovirus | 2 | 2024 | 52 | 0.390 |
Why?
|
| Hospitals, Pediatric | 7 | 2024 | 801 | 0.380 |
Why?
|
| Vaccination Coverage | 2 | 2025 | 37 | 0.370 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 1175 | 0.360 |
Why?
|
| Information Systems | 1 | 2010 | 29 | 0.320 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2026 | 500 | 0.320 |
Why?
|
| Rhinovirus | 3 | 2025 | 66 | 0.320 |
Why?
|
| Genotype | 8 | 2025 | 2655 | 0.310 |
Why?
|
| Autism Spectrum Disorder | 3 | 2021 | 444 | 0.300 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2023 | 209 | 0.290 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 319 | 0.290 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 701 | 0.290 |
Why?
|
| Pandemics | 7 | 2026 | 1169 | 0.290 |
Why?
|
| Disease Outbreaks | 2 | 2021 | 315 | 0.280 |
Why?
|
| Vaccines, Attenuated | 8 | 2022 | 174 | 0.280 |
Why?
|
| Hepatitis B Vaccines | 2 | 2026 | 49 | 0.260 |
Why?
|
| Vaccines | 2 | 2023 | 383 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3095 | 0.240 |
Why?
|
| Mothers | 3 | 2024 | 372 | 0.240 |
Why?
|
| Feces | 8 | 2025 | 725 | 0.240 |
Why?
|
| Pediatrics | 1 | 2016 | 1243 | 0.240 |
Why?
|
| Croup | 1 | 2025 | 14 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 545 | 0.230 |
Why?
|
| Bronchiolitis | 1 | 2025 | 124 | 0.210 |
Why?
|
| Hepatitis B | 1 | 2026 | 174 | 0.210 |
Why?
|
| Pregnancy | 7 | 2026 | 7588 | 0.210 |
Why?
|
| Ambulatory Care | 2 | 2026 | 408 | 0.210 |
Why?
|
| Professionalism | 1 | 2024 | 45 | 0.210 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2024 | 15 | 0.210 |
Why?
|
| Drug Prescriptions | 1 | 2025 | 230 | 0.200 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2026 | 259 | 0.200 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 97 | 0.200 |
Why?
|
| Influenza B virus | 4 | 2025 | 102 | 0.200 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 153 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2026 | 392 | 0.190 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 32 | 0.190 |
Why?
|
| Parents | 5 | 2021 | 1121 | 0.190 |
Why?
|
| Caliciviridae Infections | 1 | 2025 | 289 | 0.190 |
Why?
|
| Prenatal Care | 1 | 2025 | 346 | 0.190 |
Why?
|
| Pneumonia | 1 | 2025 | 341 | 0.180 |
Why?
|
| Norovirus | 1 | 2025 | 288 | 0.180 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 35 | 0.180 |
Why?
|
| Turbinates | 1 | 2021 | 13 | 0.180 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.180 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3851 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2021 | 512 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 173 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 44 | 0.170 |
Why?
|
| Infant, Premature | 1 | 2026 | 858 | 0.160 |
Why?
|
| Mobile Health Units | 1 | 2020 | 29 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2022 | 285 | 0.150 |
Why?
|
| Outpatients | 1 | 2021 | 266 | 0.150 |
Why?
|
| Family Health | 1 | 2020 | 251 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 123 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 778 | 0.150 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 16 | 0.150 |
Why?
|
| Antigens, Viral | 3 | 2024 | 395 | 0.140 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 6 | 0.140 |
Why?
|
| Child, Hospitalized | 3 | 2026 | 79 | 0.140 |
Why?
|
| Family Characteristics | 3 | 2025 | 98 | 0.140 |
Why?
|
| Bites and Stings | 1 | 2018 | 31 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1574 | 0.140 |
Why?
|
| Chikungunya Fever | 1 | 2018 | 32 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 913 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 403 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
|
| Cost of Illness | 3 | 2025 | 291 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 130 | 0.130 |
Why?
|
| Dengue | 1 | 2018 | 123 | 0.130 |
Why?
|
| Autistic Disorder | 1 | 2020 | 399 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2018 | 140 | 0.120 |
Why?
|
| Coinfection | 1 | 2018 | 192 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 774 | 0.120 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 25 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2023 | 815 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 368 | 0.110 |
Why?
|
| Genome, Viral | 1 | 2016 | 159 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 380 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 140 | 0.110 |
Why?
|
| Database Management Systems | 1 | 2014 | 27 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 244 | 0.110 |
Why?
|
| Phylogeny | 1 | 2016 | 716 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2010 | 27 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2585 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 360 | 0.100 |
Why?
|
| Risk Factors | 5 | 2026 | 11020 | 0.090 |
Why?
|
| Adult | 5 | 2026 | 31747 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2022 | 67 | 0.090 |
Why?
|
| Hospitals | 2 | 2026 | 445 | 0.080 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 42 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 45 | 0.080 |
Why?
|
| Time Factors | 3 | 2025 | 6283 | 0.070 |
Why?
|
| Young Adult | 2 | 2025 | 10128 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2705 | 0.070 |
Why?
|
| Informed Consent | 1 | 2010 | 343 | 0.070 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2026 | 59 | 0.060 |
Why?
|
| Palivizumab | 1 | 2026 | 48 | 0.060 |
Why?
|
| Absenteeism | 1 | 2024 | 20 | 0.060 |
Why?
|
| Vaccination Refusal | 1 | 2024 | 19 | 0.050 |
Why?
|
| Vomiting | 1 | 2025 | 105 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2024 | 39 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5124 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2023 | 6 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2024 | 164 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2148 | 0.050 |
Why?
|
| Crowding | 1 | 2023 | 12 | 0.050 |
Why?
|
| Diarrhea | 1 | 2025 | 313 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2026 | 214 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 180 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 34 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2026 | 502 | 0.050 |
Why?
|
| Coronavirus | 1 | 2022 | 27 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 792 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 19 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2024 | 414 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2022 | 123 | 0.040 |
Why?
|
| Life Support Care | 1 | 2022 | 51 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 118 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 401 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 258 | 0.040 |
Why?
|
| Length of Stay | 1 | 2026 | 1403 | 0.040 |
Why?
|
| Transients and Migrants | 1 | 2020 | 29 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2022 | 586 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 552 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2868 | 0.040 |
Why?
|
| Urban Population | 2 | 2010 | 284 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 77 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 443 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2022 | 519 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1474 | 0.030 |
Why?
|
| Critical Illness | 1 | 2022 | 616 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 984 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 455 | 0.030 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Asthma | 1 | 2025 | 928 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 32 | 0.030 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1609 | 0.030 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3718 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 503 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 544 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 329 | 0.030 |
Why?
|
| Software Design | 1 | 2014 | 22 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 138 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2014 | 44 | 0.030 |
Why?
|
| Premature Birth | 1 | 2019 | 418 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2014 | 139 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 172 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5287 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 422 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3534 | 0.020 |
Why?
|
| Presumed Consent | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hospitals, Maternity | 1 | 2010 | 8 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 934 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 237 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 429 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2026 | 17748 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 21288 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2315 | 0.010 |
Why?
|
| Middle Aged | 1 | 2025 | 28946 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3428 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1601 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 6197 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 13025 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34262 | 0.010 |
Why?
|